Research programme: alpha-2 macroglobulin therapeutics - Cytonics

Drug Profile

Research programme: alpha-2 macroglobulin therapeutics - Cytonics

Alternative Names: A2M - Cytonics; Recombinant A2M - Cytonics; α-2 macroglobulin - Cytonics; α2M - Cytonics

Latest Information Update: 19 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytonics Corporation
  • Class Proteins
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoarthritis

Highest Development Phases

  • Preclinical Diabetic foot ulcer; Osteoarthritis

Most Recent Events

  • 17 Mar 2015 Preclinical trials in Diabetic foot ulcer in USA (unspecified route) prior to March 2015
  • 26 Jul 2014 Research programme: alpha-2 macroglobulin - Cytonics is available for licensing as of 26 Jul 2014.
  • 22 Jul 2014 Preclinical trials in Osteoarthritis in USA before July 2014 (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top